I Spy CPhI - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

I Spy CPhI


Pharmaceutical Technology Europe
Volume 23, Issue 9


Rich Whitworth
Summer can often feel like a quiet month for the pharma industry in Europe. With holidays taken by so many staff, business can be quiet and out-of-office notifications abound. But in autumn, the beast awakens from its slumber.

And it does so with a number of important events, of which CPhI is one of the biggest. Come October 25, almost 30000 people from over 140 countries will come together to network, discuss the latest industry trends and hopefully forge new partnerships.

In current economic times, such shows can seem a financial burden, but the opportunity to meet people face-to-face, for me, is becoming less frequent, and to have such large numbers from the industry all under one roof is a compelling enough reason to attend. But we are also at a time of great change, with a large number of increasingly hot topics: rise of generics, emerging markets, biosimilars and biobetters, supply chain security... the list goes on. Being able to talk with others in the industry not only gives us insight into where we are now, but also, more importantly, where we might be heading.

This year, the majority of the PTE team will be attending the show in Frankfurt at booth: 51F53. You are more than welcome to visit us to let us know what's happening in your corner of the market, or to tell us about something exciting you've seen. We will be active online, providing daily show blogs and feeding important news through our twitter account. If you're not already a follower, and especially if you're not able to attend the show but want to be kept up-to-date, then head to http://PharmTech.com/twitter to join us. All of our activities will also be highlighted on a special CPhI page at http://PharmTech.com/CPhI.

As always, you're free to contact me directly, by email, but hopefully we may have a chance to meet in person soon.

Best wishes,
Rich Whitworth
Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here